136 related articles for article (PubMed ID: 37770282)
1. Safety and effectiveness of direct-acting antiviral drugs in the treatment of hepatitis C in patients with inflammatory bowel disease.
Martin-Cardona A; Horta D; Florez-Diez P; Vela M; Mesonero F; Ramos Belinchón C; García MJ; Masnou H; de la Peña-Negro L; Suarez Ferrer C; Casanova MJ; Durán MO; Peña E; Calvet X; Fernández-Prada SJ; González-Muñoza C; Piqueras M; Rodríguez-Lago I; Sainz E; Bas-Cutrina F; Mancediño Marcos N; Ojeda A; Orts B; Sicilia B; García AC; Domènech E; Esteve M;
Dig Liver Dis; 2024 Mar; 56(3):468-476. PubMed ID: 37770282
[TBL] [Abstract][Full Text] [Related]
2. Direct-acting antivirals for chronic hepatitis C.
Jakobsen JC; Nielsen EE; Feinberg J; Katakam KK; Fobian K; Hauser G; Poropat G; Djurisic S; Weiss KH; Bjelakovic M; Bjelakovic G; Klingenberg SL; Liu JP; Nikolova D; Koretz RL; Gluud C
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD012143. PubMed ID: 28922704
[TBL] [Abstract][Full Text] [Related]
3. Direct-acting antivirals for chronic hepatitis C.
Jakobsen JC; Nielsen EE; Feinberg J; Katakam KK; Fobian K; Hauser G; Poropat G; Djurisic S; Weiss KH; Bjelakovic M; Bjelakovic G; Klingenberg SL; Liu JP; Nikolova D; Koretz RL; Gluud C
Cochrane Database Syst Rev; 2017 Jun; 6(6):CD012143. PubMed ID: 28585310
[TBL] [Abstract][Full Text] [Related]
4. High rate of sustained virological response with direct-acting antivirals in haemophiliacs with HCV infection: A multicenter study.
Mancuso ME; Linari S; Santagostino E; Bartolozzi D; D'Ambrosio R; Borghi M; Lampertico P; Peyvandi F; Castaman G; Aghemo A
Liver Int; 2020 May; 40(5):1062-1068. PubMed ID: 31876354
[TBL] [Abstract][Full Text] [Related]
5. Safety and effectiveness of direct-acting antivirals in patients with chronic hepatitis C and chronic kidney disease.
Ryu JE; Song MJ; Kim SH; Kwon JH; Yoo SH; Nam SW; Nam HC; Kim HY; Kim CW; Yang H; Bae SH; Song DS; Chang UI; Yang JM; Lee SW; Lee HL; Lee SK; Sung PS; Jang JW; Choi JY; Yoon SK
Korean J Intern Med; 2022 Sep; 37(5):958-968. PubMed ID: 35981893
[TBL] [Abstract][Full Text] [Related]
6. Timing Strategies of Direct-Acting Antivirals and Biologics Administration in HCV-Infected Subjects with Inflammatory Bowel Diseases.
Imperatore N; Castiglione F; Rispo A; Sessa A; Caporaso N; Morisco F
Front Pharmacol; 2017; 8():867. PubMed ID: 29209223
[No Abstract] [Full Text] [Related]
7. Direct-acting antiviral treatment in adults infected with hepatitis C virus: Reactivation of hepatitis B virus coinfection as a further challenge.
De Monte A; Courjon J; Anty R; Cua E; Naqvi A; Mondain V; Cottalorda J; Ollier L; Giordanengo V
J Clin Virol; 2016 May; 78():27-30. PubMed ID: 26967675
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of treatment of hepatitis C in patients with inflammatory bowel disease.
Allen AM; Kim WR; Larson J; Loftus EV
Clin Gastroenterol Hepatol; 2013 Dec; 11(12):1655-60.e1. PubMed ID: 23891915
[TBL] [Abstract][Full Text] [Related]
9. Histopathology and the predominantly progressive, indeterminate and predominately regressive score in hepatitis C virus patients after direct-acting antivirals therapy.
Huang R; Rao HY; Yang M; Gao YH; Wang J; Jin Q; Ma DL; Wei L
World J Gastroenterol; 2021 Feb; 27(5):404-415. PubMed ID: 33584072
[TBL] [Abstract][Full Text] [Related]
10. Evolution of eGFR in chronic HCV patients receiving sofosbuvir-based or sofosbuvir-free direct-acting antivirals.
Liu CH; Lee MH; Lin JW; Liu CJ; Su TH; Tseng TC; Chen PJ; Chen DS; Kao JH
J Hepatol; 2020 May; 72(5):839-846. PubMed ID: 31790766
[TBL] [Abstract][Full Text] [Related]
11. Safety and effectiveness of direct acting antivirals for treatment of hepatitis C virus in patients with solid organ transplantation.
Mansour M; Hill L; Kerr J
Transpl Infect Dis; 2018 Dec; 20(6):e12972. PubMed ID: 30080955
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis B Virus Reactivation Associated With Direct-Acting Antiviral Therapy for Chronic Hepatitis C Virus: A Review of Cases Reported to the U.S. Food and Drug Administration Adverse Event Reporting System.
Bersoff-Matcha SJ; Cao K; Jason M; Ajao A; Jones SC; Meyer T; Brinker A
Ann Intern Med; 2017 Jun; 166(11):792-798. PubMed ID: 28437794
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of direct-acting antiviral agents for HCV in mild-to-moderate chronic kidney disease.
Ridruejo E; Garcia-Agudo R; Mendizabal M; Aoufi-Rabih S; Dixit V; Silva M; Fabrizi F
Nefrologia (Engl Ed); 2020; 40(1):46-52. PubMed ID: 31229261
[TBL] [Abstract][Full Text] [Related]
14. Pan-genotypic direct-acting antivirals for patients with hepatitis C virus infection and chronic kidney disease stage 4 or 5.
Liu CH; Kao JH
Hepatol Int; 2022 Oct; 16(5):1001-1019. PubMed ID: 35876967
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness And Safety Of Direct Acting Antiviral Agents In Thalassaemic Patients With Chronic Hepatitis C.
Parkash A; Merchant AA; Ahmed SH; Hussain W; Hayat M; Memon NA
J Ayub Med Coll Abbottabad; 2022; 34(3):447-451. PubMed ID: 36377154
[TBL] [Abstract][Full Text] [Related]
16. The clinical impact of direct-acting antiviral treatment on patients affected by hepatitis C virus-related oral lichen planus: a cohort study.
Di Stasio D; Lucchese A; Romano A; Adinolfi LE; Serpico R; Marrone A
Clin Oral Investig; 2022 Aug; 26(8):5409-5417. PubMed ID: 35477818
[TBL] [Abstract][Full Text] [Related]
17. Prospective Comparison of Hepatocellular Carcinoma Behavior and Survival of Patients who Did or Did not Receive HCV Direct-Acting Antivirals.
El-Kassas M; Sayed H; Omran D; Eldahrouty AH; Elbaz T; Kamal E
Asian Pac J Cancer Prev; 2023 Feb; 24(2):597-605. PubMed ID: 36853310
[TBL] [Abstract][Full Text] [Related]
18. The influence of immunosuppressants on direct-acting antiviral therapy is dependent on the hepatitis C virus genotype.
Frey A; Piras-Straub K; Walker A; Timm J; Gerken G; Herzer K
Transpl Infect Dis; 2018 Feb; 20(1):. PubMed ID: 29111569
[TBL] [Abstract][Full Text] [Related]
19. The efficacy and safety of direct-acting antiviral regimens for end-stage renal disease patients with HCV infection: a systematic review and network meta-analysis.
Chen R; Xiong Y; Zeng Y; Wang X; Xiao Y; Zheng Y
Front Public Health; 2023; 11():1179531. PubMed ID: 37841743
[TBL] [Abstract][Full Text] [Related]
20. Direct-Acting Antivirals in Hepatitis C Virus-Associated Diffuse Large B-cell Lymphomas.
Merli M; Frigeni M; Alric L; Visco C; Besson C; Mannelli L; Di Rocco A; Ferrari A; Farina L; Pirisi M; Piazza F; Loustaud-Ratti V; Arcari A; Marino D; Sica A; Goldaniga M; Rusconi C; Gentile M; Cencini E; Benanti F; Rumi MG; Ferretti VV; Grossi P; Gotti M; Sciarra R; Tisi MC; Cano I; Zuccaro V; Passamonti F; Arcaini L
Oncologist; 2019 Aug; 24(8):e720-e729. PubMed ID: 30552159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
